Regulatory T cells, tumour immunity and immunotherapy

Nature Reviews Immunology

Volumn 6, Issue 4, 2006, Pages 295-307

  Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR ANTIBODY; GRANZYME A; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; PERFORIN; TSUKUBAENOLIDE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CELL FUNCTION; CELL KILLING; CELLULAR IMMUNITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LYMPH NODE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 33645286546     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1806     Document Type: Review

References (145)

1. Shevach, E. M. Fatal attraction: tumours beckon regulatory T cells. Nature Med. 10, 900-901 (2004).
2. Gershon, R. K. & Kondo, K. Infectious immunological tolerance. Immunology 21, 903-914 (1971).
3. Gershon, R. K. & Kondo, K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18, 723-737 (1970).
4. Fujimoto, S., Creene, M. & Sehon, A. H. Immunosuppressor T cells in tumour bearing host. Immunol. Commun. 4, 201-217 (1975).
5. Berendt, M. J. & North, R. J. T-cell-mediated suppression of anti-tumour immunity. An explanation for progressive growth of an immunogenic tumour. J. Exp. Med. 151, 69-80 (1980).
6. Bursuker, I. & North, R. J. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J. Exp. Med. 159, 1312-1321 (1984).
7. + effector T cells. J. Exp. Med. 159, 1295-1311 (1984).
8. + regulatory T cells.
9. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
10. + regulatory T cells. Nature Immunol. 4, 330-336 (2003).
11. + T regulatory cells. Nature Immunol. 4, 337-342 (2003). References 9-11 provide evidence that FOXP3 is crucial for regulatory T-cell development and function.
12. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997). The first study showing that functional regulatory T cells can be induced.
13. Weiner, H. L. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol. Rev. 182, 207-214 (2001).
14. + regulatory thymocytes. Blood 102, 4107-4114 (2003).
15. S cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nature Immunol. 3, 237-243 (2002).
16. + regulatory T cells in the maintenance of T cell homeostasis. J. Exp. Med. 200, 1123-1134 (2004).
17. Zou, W. et al. Stromal-derived factor-1 in human tumours recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
18. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65, 5020-5026 (2005).
19. + regulatory T cells.
20. + suppressor T cells: more questions than answers. Nature Rev. Immunol. 2, 389-400 (2002). An outstanding Review that summarizes recent findings in the field of regulatory T cells and gives an outlook for future direction.
21. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004). This paper summarizes the most important experimental information to refine and revisit the concept of tumour immune surveillance.
22. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005).
23. + regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 6, 345-352 (2005).
24. Onizuka, S. et al. Tumour rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
25. + T cells, improves or promotes tumour immunity in mice.
26. van Elsas, A. et al. Elucidating the autoimmune and antitumour effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001).
27. + regulatory T cells in antitumour therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
28. + cells unmasks tumour immunogenicity leading to the rejection of late-stage tumours. J. Exp. Med. 201, 779-791 (2005).
29. +T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61, 8643-8646 (2001).
30. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2, 1 (2002).
31. + regulatory cells augments the generation of specific immune T cells in tumour-draining lymph nodes. J. Immunother. 25, 207-217 (2002).
32. + regulatory T cells leads to tumour rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13, 613-620 (2004).
33. + regulatory T cells. J. Immunol. 174, 90-98 (2005).
34. + regulatory T cells. J. Exp. Med. 202, 885-891 (2005).
35. + regulatory cells uncovers immune responses to shared murine tumour rejection antigens. Eur. J. Immunol. 32, 3267-3275 (2002).
36. + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumour immunity elicited by peptide vaccination. J. Immunol. 171, 5931-5939 (2003).
37. Barnett, B., Kryczek, I., Cheng, P., Zou, W. & Curiel, T. J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54, 369-377 (2005).
38. Dannull, J. et al. Enhancement of vaccine-mediated antitumour immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005).
39. Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L. & Rosenberg, S. A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582-592 (2005).
40. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
41. Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E. & Houghton, A. N. Concomitant tumour immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771-782 (2004).
42. + T cells and tumour immunopathogenesis in tumour patients and in tumour-bearing mice, respectively.
43. + regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunol. 3, 135-142 (2002).
44. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
45. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
46. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumour immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
47. Kwon, E. D. et al. Manipulation of T cell co-stimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA 94, 8099-8103 (1997).
48. Kwon, E. D. et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96, 15074-15079 (1999).
49. Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444-2448 (2000).
50. Hurwitz, A. A., Yu, T. F., Leach, D. R. & Allison, J. P. CTLA-4 blockade synergizes with tumour-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95, 10067-10071 (1998).
51. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumours accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
52. Espenschied, J. et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumour model. J. Immunol. 170, 3401-3407 (2003).
53. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
54. Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712-4717 (2003). References 53 and 54 report clinical trials that show that CTLA4 blockade can induce tumour regression as well as severe, but manageable, autoimmune diseases in patients with tumours.
55. Maker, A. V., Attia, P. & Rosenberg, S. A. Analysis of the cellular mechanism of antitumour responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746-7754 (2005).
56. + regulatory T cell function. Eur. J. Immunol. 34, 2996-3005 (2004).
57. Rollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K. & Wagner, H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 145, 455-459 (1977).
58. Glaser, M. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol. 48, 339-345 (1979).
59. Yoshida, S., Nomoto, K., Himeno, K. & Takeya, K. Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin. Exp. Immunol. 38, 211-217 (1979).
60. + suppressor-inducer T-cells. Cancer Res. 48, 1671-1675 (1988).
61. + suppressor T-cells. Cancer Res. 49, 1649-1654 (1989).
62. Awwad, M. & North, R. J. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65, 87-92 (1988).
63. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868 (2005).
64. +T cells to the antitumour immune response. J. Exp. Med. 201, 1591-1602 (2005).
65. + regulatory T cells suppress tumour immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumours to be curative. Eur. J. Immunol. 34, 336-344 (2004).
66. + regulatory T cells. Nature Med. 11, 1238-1243 (2005).
67. Von Herrath, M. G. & Harrison, L. C. Regulatory Lymphocytes: antigen-induced regulatory T cells in autoimmunity. Nature Rev. Immunol. 3, 223-232 (2003).
68. Khong, H. T. & Restifo, N. P. Natural selection of tumour variants in the generation of 'tumour escape' phenotypes. Nature Immunol. 3, 999-1005 (2002). An outstanding review of tumour immune-evasion mechanisms.
69. + T cells are increased in patients with tumours and can suppress T-cell activation in vitro.
70. Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
71. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62, 5267-5272 (2002).
72. Wolf, A. M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612 (2003).
73. Ichihara, F. et al. Increased populations of regulatory T cells in peripheral blood and tumour-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9, 4404-4408 (2003).
74. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099 (2003).
75. Ormandy, L. A. et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457-2464 (2005).
76. Karube, K. et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br. J. Haematol. 126, 81-84 (2004).
77. Marshall, N. A. et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103, 1755-1762 (2004).
78. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453 (2004).
79. + regulatory T-cell levels in patients with melanoma. Clin. Cancer Res. 9, 2551-2559 (2003).
80. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
81. + regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 199, 1285-1291 (2004).
82. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277-285 (2004).
83. Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329-341 (2005).
84. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64, 8451-8455 (2004).
85. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
86. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
87. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
88. Chakraborty, N. G., Chattopadhyay, S., Mehrotra, S., Chhabra, A. & Mukherji, B. Regulatory T-cell response and tumour vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 65, 794-802 (2004). References 86-88 and 143 provide evidence that APCs can induce regulatory T cells in humans.
89. + regulatory T cell proliferation. J. Exp. Med. 202, 919-929 (2005).
90. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235-247 (2003).
91. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199, 1467-1477 (2004).
92. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
93. + regulatory T cells by peripheral expansion. J. Immunol. 173, 7259-7268 (2004).
94. -T cells through Foxp3 induction and downregulation of Smad7. J. Immunol. 172, 5149-5153 (2004).
95. + regulatory T cells in vivo requires B7 co-stimulation, but not the thymus. J. Exp. Med. 201, 127-137 (2005).
96. Wan, Y. Y. & Flavell, R. A. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl Acad. Sci. USA 102, 5126-5131 (2005).
97. +T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103, 449-457 (2001).
98. Moller, G. Do suppressor T cells exist? Scand J. Immunol. 27, 247-250 (1988).
99. + T cells in human cancer.
100. Hawrylowicz, C. M. & O'Garra, A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nature Rev. Immunol. 5, 271-283 (2005).
101. + T cell receptors. Immunity 21, 267-277 (2004).
102. Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I. & Marson, A. L. Reciprocal changes in tumour antigenicity and antigen-specific T cell function during tumour progression. J. Exp. Med. 200, 1581-1592 (2004).
103. + T cells in blunting the NK-cell arm of the innate immune system in tumour immunity.
104. Chen, M. L. et al. Regulatory T cells suppress tumour-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl Acad. Sci. USA 102, 419-424 (2005).
105. + regulatory T cells responsible for protection against diabetes. Proc. Natl Acad. Sci. USA 101, 4572-4577 (2004).
106. + T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl Acad. Sci. USA 100, 10878-10883 (2003).
107. Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. (in the press).
108. Kryczek, I. et al. Induction of B7-H4 on antigen presenting cells through interleukin 10: novel suppressive mode for regulatory T cells. J. Immunol. (in the press).
109. von Boehmer, H. Mechanisms of suppression by suppressor T cells. Nature Immunol. 6, 338-344 (2005).
110. + regulatory T cell function. Eur. J. Immunol. 34, 2480-2488 (2004).
111. Grossman, W. J. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589-601 (2004).
112. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174, 1783-1786 (2005).
113. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004).
114. Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nature Immunol. 4, 1206-1212 (2003).
115. Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849-861 (2003).
116. Zang, X. et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100, 10388-10392 (2003).
117. Prasad, D. V., Richards, S., Mai, X. M. & Dong, C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863-873 (2003).
118. + regulatory T cells. J. Exp. Med. 201, 681-686 (2005).
119. + helper T cell responses in cancer patients. Blood 106, 1008-1011 (2005).
120. Apostolou, I., Sarukhan, A., Klein, L. & von Boehmer, H. Origin of regulatory T cells with known specificity for antigen. Nature Immunol. 3, 756-763 (2002).
121. Zhou, G., Drake, C. G. & Levitsky, H. I. Amplification of tumour-specific regulatory T cells following therapeutic cancer vaccines. Blood 107, 628-636 (2006).
122. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
123. 389 IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma 1, 110-116 (2000).
124. Shibutani, S. et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 79, 904-913 (2005).
125. Kawai, M., Kitade, H., Mathieu, C., Waer, M. & Pirenne, J. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 79, 1073-1077 (2005).
126. + regulatory T cell function. J. Exp. Med. 196, 851-857 (2002).
127. Malek, T. R. & Bayer, A. L. Tolerance, not immunity, crucially depends on IL-2. Nature Rev. Immunol. 4, 665-674 (2004).
128. + T regulatory cell development during the neonatal period. J. Exp. Med. 201, 769-777 (2005).
129. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
130. + T cell suppressor function. J. Immunol. 172, 6519-6523 (2004).
131. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28, 120-128 (2005).
132. Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630-641 (2003). An outstanding and comprehensive review of the development of vaccination and immunotherapy for cancer. It proposes that cancer vaccines must overcome immune suppression.
133. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104, 775-780 (2004).
134. + regulatory T cells in cancer patients. Blood 107, 2409-2414 (2006).
135. Kryczek, I. et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465-472 (2005).
136. + T cells. Proc. Natl Acad. Sci. USA 101, 1969-1974 (2004).
137. + T cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
138. + memory cell pool. J. Clin. Invest. 115, 1177-1187 (2005).
139. + regulatory T cells in inflamed synovia. J. Exp. Med. 201, 1793-1803 (2005).
140. + T cells. J. Immunol. 174, 7433-7439 (2005).
141. Wakkach, A. et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617 (2003).
142. Lutz, M. B. & Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23, 445-449 (2002).
143. + regulatory T cells in vivo in humans. Blood 100, 174-177 (2002).
144. Lundqvist, A., Palmborg, A., Pavlenko, M., Levitskaya, J. & Pisa, P. Mature dendritic cells induce tumour-specific type 1 regulatory T cells. J. Immunother. 28, 229-235 (2005).
145. Wickelgren, I. Immunology. Policing the immune system. Science 306, 596-599 (2004).